Drugs / Leukocyte-poor platelet-rich plasma
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04241354 | Aug → Dec 2021 | osteoarthritis, hip | Regenerative Orthopedics and Sports Medicine | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05517434 | Jan 2025 → Jun 2026 overdue | osteoarthritis, knee | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05737173 | Aug 2020 → Sep 2022 | osteoarthritis, knee | Queen Savang Vadhana Memorial Hospital, Thailand | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07815743 | Sep 2026 → Oct 2027 expected | — | Autonomous University of Nuevo León | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leukocyte-poor platelet-rich plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07815743 ↗ |
| Known as | LP-PRP | “Leukocyte-poor platelet-rich plasma (LP-PRP) will be prepared from approximately 60 mL of autologous venous blood using a standardized manual double-centrifugation technique.” NCT07815743 ↗2“A single injection of leukocyte poor platelet rich plasma (LP-PRP) will be administered to the intra-articular space under ultrasound guidance at the treatment visit.” NCT04241354 ↗ “Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations” NCT05517434 ↗ |
| Modality | Cell therapy | “minimally manipulated autologous cellular preparations” NCT05517434 ↗ |
| Route | Other | “2 mL (or less) of LP-PRP into the osteoarthritic knee joint” NCT05517434 ↗ |